Glimisave M2 750 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2 mg and Metformin 750 mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. This dual-action formulation effectively targets multiple pathophysiological defects associated with type 2 diabetes, aiding in the reduction of fasting and postprandial blood glucose levels. Glimisave M2 750 Tablet PR is indicated for patients inadequately controlled on diet and exercise alone or those requiring combination therapy for optimal glycemic management. The extended-release formulation allows for sustained drug delivery, promoting better patient adherence and minimizing gastrointestinal side effects commonly associated with Metformin. It is essential to monitor renal function prior to and during treatment to avoid lactic acidosis risk. Dose adjustments may be necessary based on glycemic response and tolerability. This medication should be used as part of a comprehensive diabetes care plan, including lifestyle modifications such as diet and exercise, under the supervision of a healthcare professional.